Repligen is expected to report Q3 2026 revenue of $206.71 million and EPS of $0.46, with the current stock price of $176.93 trading slightly above the average analyst price target of $175.71.
Investors are primarily focused on the book-to-bill ratio, which is expected to remain above 1.0 as the bioprocessing sector continues its recovery from post-pandemic destocking.
Following a robust second quarter where organic growth reached 13%, management raised full-year 2026 guidance, signaling sustained momentum in the cell therapy and mRNA segments. Markets are also closely monitoring the integration of BioLife Solutions, an acquisition completed in early October intended to expand Repligen's leadership in fluid management and filtration.